Actively Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
Led by Pheon Therapeutics · Updated on 2026-04-17
165
Participants Needed
21
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
CONDITIONS
Official Title
A Study of PHN-012 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced or metastatic colorectal adenocarcinoma, non-small cell lung cancer, or pancreatic ductal adenocarcinoma
- Received at least one prior systemic therapy with disease progression during or after the most recent treatment
- No further standard therapy available or intolerant to standard therapy
- Measurable disease present
- ECOG performance status of 0 or 1
- Adequate organ function
- Available tumor tissue sample at screening (archival or fresh biopsy)
You will not qualify if you...
- Prior treatment with any antibody-drug conjugate containing topoisomerase-1 inhibiting payload
- Unstable central nervous system metastasis
- Persistent toxicities from previous systemic anti-cancer treatments of Grade >1
- Received systemic anti-neoplastic therapy within five half-lives or 21 days before first dose
- Received wide-field radiotherapy (>30% of marrow-bearing bones) within 28 days or focal radiation for analgesic or lytic lesions within 14 days before first dose or no recovery from side effects
- Major surgery (excluding vascular access device placement or tumor biopsies) within 28 days before first dose or no recovery from side effects
- History of non-infectious pneumonitis/interstitial lung disease requiring systemic steroids within 6 months, active or suspected NIP/ILD not ruled out by imaging at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
PHN-012-001 Site
Los Angeles, California, United States, 90033
Actively Recruiting
2
PHN-012-001 Site
San Diego, California, United States, 92037
Not Yet Recruiting
3
PHN-012-001 Site
Washington D.C., District of Columbia, United States, 20007
Actively Recruiting
4
PHN-012-001 Site
Boston, Massachusetts, United States, 02114
Actively Recruiting
5
PHN-012-001 Site
St Louis, Missouri, United States, 63108
Actively Recruiting
6
PHN-012-001 Site
Durham, North Carolina, United States, 27710
Actively Recruiting
7
PHN-012-001 Site
Portland, Oregon, United States, 97239
Actively Recruiting
8
PHN-012-001 Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
9
PHN-012-001 Site
Houston, Texas, United States, 77030
Actively Recruiting
10
PHN-012-001 Site
San Antonio, Texas, United States, 78229
Actively Recruiting
11
PHN-012-001 Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
12
PHN-012-001 Site
Barcelona, Community of Catalonia, Spain, 08023
Actively Recruiting
13
PHN-012-001 Site
Barcelona, Community of Catalonia, Spain, 08023
Not Yet Recruiting
14
PHN-012-001 Site
Barcelona, Community of Catalonia, Spain, 08035
Not Yet Recruiting
15
PHN-012-001 Site
Madrid, Madrid, Spain, 28007
Not Yet Recruiting
16
PHN-012-001 Site
Madrid, Madrid, Spain, 28027
Actively Recruiting
17
PHN-012-001 Site
Madrid, Madrid, Spain, 28034
Not Yet Recruiting
18
PHN-012-001 Site
Madrid, Madrid, Spain, 28040
Actively Recruiting
19
PHN-012-001 Site
Madrid, Madrid, Spain, 28050
Actively Recruiting
20
PHN-012-001 Site
Valencia, Valencia, Spain, 46009
Not Yet Recruiting
21
PHN-012-001 Site
Valencia, Valencia, Spain, 46010
Actively Recruiting
Research Team
M
Myles Clancy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here